13F Pro

SEC Form 4 reporting owner

Mazumdar Claire

Mazumdar Claire has filed 22 Form 4 transactions reported between November 24, 2025 and August 10, 2026, as Chief Executive Officer of Bicara Therapeutics Inc. and a reporting owner of Relay Therapeutics, Inc..

Name as filed: Mazumdar Claire

Open-market buys, 24 mo
None
reported
Open-market sales, 24 mo
$585K
4 lines
Companies
2
with Form 4 filings
Latest transaction
Aug 10, 2026
transaction date

Roles and reported holdings

  • BCAXBicara Therapeutics Inc.
    Nov 24, 2025 – Aug 10, 2026

    Chief Executive Officer

    Held directly362,152 sh as of Jul 10, 2026 · Form 4

    24 months: $585K sold

  • RLAYRelay Therapeutics, Inc.
    Jun 9, 2026

    Reporting owner

    No common-stock holding reported on a purchase, sale, gift or withholding line.

Transaction history

All 22 reported transactions, newest first. Every row links to the Form 4 on SEC EDGAR.

DateCompanyTypeSharesValueFiling
Aug 10, 2026BCAXChief Executive OfficerOption exerciseCode M · direct10,000$38K@ $3.79Form 4
Jul 10, 2026BCAXChief Executive OfficerOpen-market saleCode S · direct28$831@ $29.68Form 4
Jul 10, 2026BCAXChief Executive OfficerOpen-market saleCode S · direct9,972$283K@ $28.42Form 4
Jul 10, 2026BCAXChief Executive OfficerOption exerciseCode M · direct10,000$38K@ $3.79Form 4
Jun 9, 2026RLAYGrant or awardCode A · direct32,947—Form 4
May 18, 2026BCAXChief Executive OfficerOpen-market saleCode S · direct2,978$61K@ $20.35Form 4
May 18, 2026BCAXChief Executive OfficerOpen-market saleCode S · direct12,022$240K@ $19.96Form 4
May 18, 2026BCAXChief Executive OfficerOption exerciseCode M · direct15,000$57K@ $3.79Form 4
Apr 20, 2026BCAXChief Executive OfficerOption exerciseCode M · direct15,000$57K@ $3.79Form 4
Apr 16, 2026BCAXChief Executive OfficerOption exerciseCode M · direct7,080$39K@ $5.45Form 4
Apr 16, 2026BCAXChief Executive OfficerOption exerciseCode M · direct7,454$28K@ $3.79Form 4
Apr 16, 2026BCAXChief Executive OfficerOption exerciseCode M · direct8,226$36K@ $4.44Form 4
Mar 20, 2026BCAXChief Executive OfficerOption exerciseCode M · direct1,596$6K@ $3.79Form 4
Mar 19, 2026BCAXChief Executive OfficerOption exerciseCode M · direct6,905$26K@ $3.79Form 4
Mar 18, 2026BCAXChief Executive OfficerOption exerciseCode M · direct6,499$25K@ $3.79Form 4
Mar 9, 2026BCAXChief Executive OfficerOption exerciseCode M · direct36,766$139K@ $3.79Form 4
Mar 6, 2026BCAXChief Executive OfficerOption exerciseCode M · direct3,817$14K@ $3.79Form 4
Mar 5, 2026BCAXChief Executive OfficerOption exerciseCode M · direct1,786$7K@ $3.79Form 4
Mar 4, 2026BCAXChief Executive OfficerOption exerciseCode M · direct2,631$10K@ $3.79Form 4
Feb 2, 2026BCAXChief Executive OfficerGrant or awardCode A · direct450,000—Form 4
Dec 16, 2025BCAXChief Executive OfficerOption exerciseCode M · direct29,500$161K@ $5.45Form 4
Nov 24, 2025BCAXChief Executive OfficerOption exerciseCode M · direct41,163$156K@ $3.79Form 4

How this page is built

Every row comes from a Form 4 filed with the SEC, which officers, directors and holders of more than 10% of a company’s stock must file within two business days of a trade. Transactions are grouped by the reporting owner’s name as filed (spacing, capitals and punctuation ignored); two different people filing under an identical name would appear together, and one person filing under two spellings appears on two pages.

Open-market totals count code P purchases and code S sales over the last 24 months. The same trade reported on more than one filing is counted once; when another owner (for example a fund and its general partner) reports the identical trade, they are listed beside it. Holdings are the shares owned after the latest purchase, sale, gift or tax-withholding line, shown separately for direct and indirect ownership; an indirect figure is one holding line, not a total across every trust or entity.

This page describes what was filed with the SEC; it is not investment advice or a recommendation to buy or sell any security.